SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Germany · Delayed Price · Currency is EUR 17.36
+0.04 (0.23%)
Last updated: Jun 16, 2026, 12:59 PM CET
ETR:1SXP Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, ETR:1SXP stock has a consensus rating of "Buy" and an average price target of €19.43. The average 1-year stock price forecast is 11.92% higher than the current stock price, while the lowest is €13.00 (-25.12%) and the highest is €25.90 (+49.19%).
Price Target: €19.43 (+11.92%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ETR:1SXP stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 12 | 12 |
Financial Forecast
Revenue This Year
1.01B
from 986.21M
Increased by 2.71%
Revenue Next Year
1.09B
from 1.01B
Increased by 7.35%
EPS This Year
0.94
from 0.97
Decreased by -2.61%
EPS Next Year
1.08
from 0.94
Increased by 13.92%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.0B | ||
| Avg | 1.0B | ||
| Low | 1.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.0% | ||
| Avg | 2.7% | ||
| Low | 1.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.98 | ||
| Avg | 0.94 | ||
| Low | 0.91 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.0% | ||
| Avg | -2.6% | ||
| Low | -6.2% |